Skip to content

PROVE Trial - Positive pRessure therapy in COVid-19 infEction

A randomised controlled trial of oxygen delivery through nasal cannula or NIP masks in patients with confirmed COVID 19 infection: The PROVE Trial - PROVE

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033175
Enrollment
1800
Registered
2021-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Oxygen delivery via Materialise Passive Non-Invasive PEEP device mask : Oxygen will be delivered via the Materialise Passive Non-Invasive PEEP device mask continuously through out the d

Sponsors

George Institute for Global Health India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years 2. Laboratory confirmed COVID-19 positive infection 3. Requiring more than 40% oxygen (FiO2 > 0.4) â?? (requiring 6L or more of oxygen by Hudson mask or nasal cannula) to maintain SpO2 >93%

Exclusion criteria

Exclusion criteria: 1. Obtunded 2. The attending clinician is not committed to patient receiving mechanical ventilatory support 3. In the opinion of the treating clinician the patient is in respiratory distress and is eminently requiring escalation of treatment including intubation and mechanical ventilation 4. Currently receiving either CPAP, BiPAP, high flow nasal prongs or mechanical ventilation 5. Participants usually on home ventilation (either CPAP or BiPAP) 6. Previous participation in PROVE trial 7. Known or suspected pregnancy 8. Enrolment in the study is not in the best interest of the patient as deemed by the treating clinician

Design outcomes

Primary

MeasureTime frame
Need for escalation of respiratory support, defined as, need for CPAP, BIPAP, or invasive mechanical ventilationTimepoint: Upto 14 days following randomization

Secondary

MeasureTime frame
Costs of hospitalisationTimepoint: Continuous for the length of stay in hospital;Daily blood pressures Timepoint: Upto 14 days following randomization;Daily lowest and highest oxygen flow rates Timepoint: Upto 14 days;Daily lowest and highest oxygen saturations Timepoint: Upto 14 days;Days alive and free of ICU Timepoint: Upto 14 days;Days off workTimepoint: Continuous;Duration of InterventionTimepoint: Continuous for the length of stay in hospital;Duration of mechanical ventilation Timepoint: Upto 14 days;Dyspnoea scaleTimepoint: Upto 14 days following randomization;Episodes of aspiration pneumonia Timepoint: Continuous for the length of stay in hospital;Evidence of barotrauma defined as: clinical or radiological evidence of pneumothorax or subcutaneous emphysema Timepoint: Continuous for the length of stay in hospital;Length of stay in ICU and hospitalTimepoint: Continuous;MortalityTimepoint: At Day 28;Mortality Timepoint: At Day 7;Need for vasopressor or inotropic support Timepoint: Upto 14 days;Oxygen saturation profiles Timepoint: Immediately after commencement of interventions;Process Outcome: Duration of InterventionTimepoint: Continuous for the length of stay in hospital;Process Outcome: Ease of use score as determined by the Health Care Professional Timepoint: Continuous for the length of stay in hospital;Process Outcome: Measurement of PEEP in the NIP mask in a cohort of 50 patients Timepoint: Continuous for the length of stay in hospital

Countries

India

Contacts

Public ContactProfessor Vivekanand Jha

George Institute for Global Health

vjha@georgeinstitute.org.in911141588091

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026